tiprankstipranks
Trending News
More News >

Satellos Bioscience Reports Promising Phase 1b Trial Results for DMD Treatment

Story Highlights
  • Satellos Bioscience’s SAT-3247 showed safety and potential grip strength improvement in DMD patients.
  • The company plans a Phase 2 trial for SAT-3247, aiming to enhance DMD treatment options.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Satellos Bioscience Reports Promising Phase 1b Trial Results for DMD Treatment

Don’t Miss TipRanks’ Half-Year Sale

Satellos Bioscience ( (TSE:MSCL) ) has issued an update.

Satellos Bioscience has announced promising results from its Phase 1b trial of SAT-3247, a treatment for Duchenne Muscular Dystrophy (DMD). The trial demonstrated that SAT-3247 was safe and well-tolerated, with a potential trend towards improved grip strength in patients. The company plans to advance to a placebo-controlled Phase 2 trial, indicating potential advancements in treatment options for DMD patients.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.

To see Spark’s full report on TSE:MSCL stock, click here.

More about Satellos Bioscience

Satellos Bioscience Inc. is a biotechnology company focused on developing small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders.

Average Trading Volume: 148,006

Technical Sentiment Signal: Sell

Current Market Cap: C$109.5M

Find detailed analytics on MSCL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1